Citadel Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.1M Buy
48,000
+28,300
+144% +$2M ﹤0.01% 5197
2025
Q4
$1.33M Sell
19,700
-31,300
-61% -$2.11M ﹤0.01% 6791
2025
Q3
$3.74M Buy
51,000
+4,100
+9% +$272K ﹤0.01% 4896
2025
Q2
$2.44M Buy
46,900
+19,800
+73% +$1.13M ﹤0.01% 5349
2025
Q1
$1.73M Sell
27,100
-10,800
-28% -$627K ﹤0.01% 5814
2024
Q4
$1.81M Sell
37,900
-1,700
-4% -$87.2K ﹤0.01% 5840
2024
Q3
$2.27M Buy
39,600
+20,500
+107% +$1.18M ﹤0.01% 5302
2024
Q2
$1M Buy
19,100
+1,400
+8% +$61.4K ﹤0.01% 6576
2024
Q1
$720K Sell
17,700
-1,300
-7% -$48.7K ﹤0.01% 7611
2023
Q4
$702K Sell
19,000
-17,100
-47% -$644K ﹤0.01% 7391
2023
Q3
$1.38M Buy
36,100
+5,100
+16% +$209K ﹤0.01% 5936
2023
Q2
$1.12M Buy
31,000
+6,000
+24% +$205K ﹤0.01% 6230
2023
Q1
$955K Sell
25,000
-16,900
-40% -$793K ﹤0.01% 6872
2022
Q4
$2.38M Buy
41,900
+9,200
+28% +$471K ﹤0.01% 5142
2022
Q3
$1.29M Sell
32,700
-30,900
-49% -$1.37M ﹤0.01% 6443
2022
Q2
$2.8M Buy
63,600
+8,600
+16% +$372K ﹤0.01% 4884
2022
Q1
$2.19M Sell
55,000
-9,400
-15% -$335K ﹤0.01% 5888
2021
Q4
$2.59M Sell
64,400
-4,400
-6% -$164K ﹤0.01% 5633
2021
Q3
$2.8M Buy
68,800
+18,600
+37% +$778K ﹤0.01% 5537
2021
Q2
$2.28M Buy
50,200
+8,900
+22% +$394K ﹤0.01% 6266
2021
Q1
$1.72M Sell
41,300
-36,400
-47% -$1.66M ﹤0.01% 6764
2020
Q4
$3.32M Buy
77,700
+10,900
+16% +$392K ﹤0.01% 4410
2020
Q3
$1.76M Sell
66,800
-27,800
-29% -$774K ﹤0.01% 4968
2020
Q2
$2.54M Buy
94,600
+50,200
+113% +$1.13M ﹤0.01% 4149
2020
Q1
$799K Sell
44,400
-56,100
-56% -$1.06M ﹤0.01% 5711
2019
Q4
$1.78M Buy
100,500
+43,900
+78% +$760K ﹤0.01% 4602
2019
Q3
$878K Buy
56,600
+5,600
+11% +$92.2K ﹤0.01% 5811
2019
Q2
$876K Buy
51,000
+10,900
+27% +$176K ﹤0.01% 5908
2019
Q1
$646K Sell
40,100
-115,600
-74% -$1.87M ﹤0.01% 6356
2018
Q4
$2.28M Buy
155,700
+97,200
+166% +$1.55M ﹤0.01% 3945
2018
Q3
$1.06M Buy
58,500
+5,000
+9% +$87.6K ﹤0.01% 5430
2018
Q2
$903K Buy
53,500
+400
+0.8% +$7.56K ﹤0.01% 5396
2018
Q1
$1.04M Sell
53,100
-58,600
-52% -$1.13M ﹤0.01% 4744
2017
Q4
$2.26M Buy
111,700
+45,600
+69% +$838K ﹤0.01% 3467
2017
Q3
$1.15M Buy
66,100
+14,900
+29% +$202K ﹤0.01% 4127
2017
Q2
$656K Buy
51,200
+15,100
+42% +$202K ﹤0.01% 4735
2017
Q1
$468K Sell
36,100
-24,200
-40% -$306K ﹤0.01% 5139
2016
Q4
$596K Buy
60,300
+5,000
+9% +$54.8K ﹤0.01% 4622
2016
Q3
$668K Buy
55,300
+17,400
+46% +$178K ﹤0.01% 4405
2016
Q2
$327K Sell
37,900
-5,500
-13% -$54.3K ﹤0.01% 5088
2016
Q1
$411K Buy
43,400
+10,600
+32% +$99.7K ﹤0.01% 4675
2015
Q4
$568K Sell
32,800
-1,900
-5% -$30.3K ﹤0.01% 4292
2015
Q3
$466K Sell
34,700
-200
-0.6% -$4.02K ﹤0.01% 4900
2015
Q2
$788K Buy
34,900
+10,300
+42% +$181K ﹤0.01% 4303
2015
Q1
$351K Sell
24,600
-36,500
-60% -$526K ﹤0.01% 5434
2014
Q4
$590K Buy
61,100
+17,000
+39% +$151K ﹤0.01% 4481
2014
Q3
$401K Sell
44,100
-12,300
-22% -$117K ﹤0.01% 4913
2014
Q2
$557K Buy
56,400
+27,600
+96% +$234K ﹤0.01% 4254
2014
Q1
$366K Sell
28,800
-7,700
-21% -$114K ﹤0.01% 4778
2013
Q4
$547K Buy
36,500
+16,700
+84% +$215K ﹤0.01% 3906
2013
Q3
$219K Sell
19,800
-1,800
-8% -$15K ﹤0.01% 4673
2013
Q2
$172K Buy
+21,600
New +$138K ﹤0.01% 4792

Other funds holding HALO

Citadel Advisors's HALO Position: Q1 2026 in Review

Citadel Advisors opened a new position in Halozyme (HALO) in Q1 2026: 191,051 shares worth $12.3M. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HALO as recently as Q3 2025.

Citadel Advisors first reported a position in HALO in Q2 2013 and has held it in 49 quarters since. The position peaked at $60.4M in Q4 2024. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Citadel Advisors held 191,051 shares of Halozyme worth $12.3M as of Q1 2026.
  • Halozyme was a new Citadel Advisors position in Q1 2026.
  • Halozyme made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2954 holding.
  • Citadel Advisors first reported a position in Halozyme in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Halozyme position peaked at $60.4M in Q4 2024.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.